MedTrace Logo

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

NCT03207815 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-01-21

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.

Conditions

  • Noninfectious Uveitis

Interventions

DRUG

Filgotinib

Tablet(s) administered orally

DRUG

Placebo to match filgotinib

Tablet(s) administered orally

DRUG

Prednisone

Tablet(s) administered orally

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-26
Primary Completion
2020-12-29
Completion
2021-04-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Israel
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03207815 on ClinicalTrials.gov